Lord, Abbett & Co
RYTM icon

Lord, Abbett & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

Lord, Abbett & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.3M Sell
348,953
-270,589
-44% -$26.3M 0.1% 220
2025
Q4 		$66.3M Buy
619,542
+43,558
+8% +$4.62M 0.2% 132
2025
Q3 		$58.2M Buy
575,984
+371,709
+182% +$34.5M 0.17% 148
2025
Q2 		$12.9M Buy
204,275
+68,915
+51% +$4.22M 0.04% 348
2025
Q1 		$7.17M Sell
135,360
-25,291
-16% -$1.4M 0.03% 419
2024
Q4 		$8.99M Buy
160,651
+58,005
+57% +$3.2M 0.03% 397
2024
Q3 		$5.38M Buy
102,646
+55
+0.1% +$2.63K 0.02% 473
2024
Q2 		$4.21M Sell
102,591
-178,566
-64% -$7.13M 0.01% 475
2024
Q1 		$12.2M Sell
281,157
-2,361
-0.8% -$103K 0.04% 373
2023
Q4 		$13M Buy
+283,518
New +$8.94M 0.05% 370

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Lord, Abbett & Co's RYTM Position: Q1 2026 in Review

Lord, Abbett & Co reduced its Rhythm Pharmaceuticals (RYTM) stake by 44% in Q1 2026, selling an estimated $26.3M and leaving 348,953 shares worth $30.3M. The position accounts for 0.1% of the portfolio, ranked #220.

Lord, Abbett & Co first reported a position in RYTM in Q4 2023 and has held it in 10 quarters since. The position peaked at $66.3M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Lord, Abbett & Co held 348,953 shares of Rhythm Pharmaceuticals worth $30.3M as of Q1 2026.
  • Lord, Abbett & Co sold 270,589 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $26.3M.
  • Rhythm Pharmaceuticals made up 0.1% of Lord, Abbett & Co's portfolio in Q1 2026, its #220 holding.
  • Lord, Abbett & Co first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Lord, Abbett & Co's Rhythm Pharmaceuticals position peaked at $66.3M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.